[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"skill:01M7DPVVRFCF5HQ3SYVXWMMCBR":3,"skill-same:01M7DPVVRFCF5HQ3SYVXWMMCBR":108},{"skillNo":4,"name":5,"nameZh":6,"description":7,"descriptionZh":6,"repositoryFullName":8,"ownerLogin":9,"ownerAvatarUrl":10,"ownerAccountNo":11,"ownerDisplayName":12,"repositoryNo":13,"starsCount":14,"licenseSpdxId":15,"licenseFileUrl":6,"sourceHtmlUrl":16,"categories":17,"keywords":18,"publishedAt":19,"linkOnly":20,"markdownContent":21,"markdownBody":22,"frontMatter":23,"refName":41,"commitSha":42,"skillDirectory":43,"forksCount":14,"repositoryHtmlUrl":44,"repositoryHomepageUrl":6,"ownerHtmlUrl":45,"ownerBlogUrl":6,"ownerDescription":46,"updatedAt":47,"install":48,"resources":61},"01M7DPVVRFCF5HQ3SYVXWMMCBR","clinical-research",null,"Use when designing a prospective clinical study before submission — selecting and classifying endpoints (primary \u002F key-secondary \u002F exploratory, with surrogate-endpoint flagging), estimating sample size and power for two-arm designs (means \u002F proportions \u002F survival), or scoring a study plan for feasibility and a GO \u002F GO-WITH-CONDITIONS \u002F REDESIGN \u002F NO-GO phase-gate decision. Every output is an ESTIMATE plus a named human owner (clinician \u002F biostatistician \u002F regulatory owner) — never clinical fact, never a finished protocol. Distinct from ra-qm-team, which handles the regulatory\u002FQM submission (ISO 13485, EU MDR, FDA 510(k)\u002FPMA\u002FQSR), not the study design.","Prudhviraj101\u002FX_Agent","Prudhviraj101","https:\u002F\u002Favatars.githubusercontent.com\u002Fu\u002F141725940?v=4","01M7DN1Y3RW3QD7692M89MPS3D","MALLA PRUDHVI RAJ S S N MURTHY","01M7DN1Y4A763ESFP16P13EE19",0,"MIT","https:\u002F\u002Fgithub.com\u002FPrudhviraj101\u002FX_Agent\u002Fblob\u002Fmain\u002F.agents\u002Fskills\u002Falirezarezvani\u002Fresearch-ops__clinical-research\u002FSKILL.md",[],[],"2026-11-15 14:19:17",false,"---\nname: clinical-research\ndescription: Use when designing a prospective clinical study before submission — selecting and classifying endpoints (primary \u002F key-secondary \u002F exploratory, with surrogate-endpoint flagging), estimating sample size and power for two-arm designs (means \u002F proportions \u002F survival), or scoring a study plan for feasibility and a GO \u002F GO-WITH-CONDITIONS \u002F REDESIGN \u002F NO-GO phase-gate decision. Every output is an ESTIMATE plus a named human owner (clinician \u002F biostatistician \u002F regulatory owner) — never clinical fact, never a finished protocol. Distinct from ra-qm-team, which handles the regulatory\u002FQM submission (ISO 13485, EU MDR, FDA 510(k)\u002FPMA\u002FQSR), not the study design.\nversion: 2.9.0\nauthor: claude-code-skills\nlicense: MIT\ntags: [research-ops, clinical-research, study-design, endpoint, sample-size, power, phase-gate, biostatistics]\ncompatible_tools: [claude-code, codex-cli, cursor, antigravity, opencode, gemini-cli]\n---\n\n# clinical-research\n\nProspective clinical study DESIGN: endpoints, sample size \u002F power, and phase-gate feasibility. Every output is an **estimate with stated assumptions** routed to a **named human owner**. This skill never gives clinical advice as fact and never substitutes for a biostatistician or regulatory affairs.\n\n## Purpose\n\nR&D clinical teams, medical monitors, and biostatistics functions live at the moment between *we-have-a-hypothesis* and *we-have-a-protocol-ready-for-submission*. This skill structures three of the hardest design decisions:\n\nThree deterministic tools:\n\n1. `sample_size_estimator.py` — Closed-form power \u002F sample-size for two-arm **means** (Cohen's d), **proportions** (normal approximation), and **survival** (Schoenfeld events). Inflates for dropout. Prints an \"ESTIMATE — confirm with a biostatistician\" banner.\n2. `endpoint_selector.py` — Scores candidate endpoints across 5 weighted dimensions (clinical relevance, measurability, regulatory acceptance, sensitivity-to-change, burden) and classifies each as **PRIMARY \u002F KEY-SECONDARY \u002F EXPLORATORY**. Penalizes unvalidated surrogate endpoints.\n3. `phase_gate_scorer.py` — Scores a study plan 0-100 across recruitment feasibility, endpoint readiness, statistical power, operational complexity, and budget fit; returns **GO \u002F GO-WITH-CONDITIONS \u002F REDESIGN \u002F NO-GO** plus the named owners who must sign.\n\n## When to use\n\nInvoke this skill when:\n\n- You are choosing a primary endpoint and need to defend it against surrogate-endpoint scrutiny.\n- You need a defensible first sample-size estimate for a protocol synopsis.\n- A study plan needs a feasibility read before a phase-gate review.\n- You are pressure-testing whether the planned enrollment is achievable given the eligible population and sites.\n\n**Do NOT use this skill to**: prepare a regulatory submission or clinical evaluation report (use `ra-qm-team`), find or position a grant (use `research\u002Fgrants`), design a live product A\u002FB experiment (use `product-team\u002Fexperiment-designer`), or replace a biostatistician's final sample-size justification.\n\n## Workflow\n\n1. **Draft the synopsis** — Fill `assets\u002Fprotocol_synopsis_template.md` (objectives, design, population, endpoints, statistical plan placeholder, owners-to-sign).\n2. **Select the endpoint** — Run `endpoint_selector.py --input endpoints.json --profile {drug|device|biologic|diagnostic|digital-therapeutic}`. Read the classification + surrogate flags. If >1 primary, plan multiplicity control.\n3. **Estimate the sample size** — Run `sample_size_estimator.py --design {means|proportions|survival} ...`. Trace the effect\u002Fdifference\u002FHR to a published or anchor-based source; inflate for dropout.\n4. **Score feasibility** — Run `phase_gate_scorer.py --input study.json --profile \u003Csame> --phase {1|2|3|4}`. Read the verdict + blockers + named owners.\n5. **Route for sign-off** — Assemble the synopsis + estimates into the gate packet. The packet is **a recommendation**; a biostatistician, medical monitor, and regulatory owner sign.\n\n## Scripts\n\n| Script | Purpose | Profiles |\n|---|---|---|\n| `scripts\u002Fsample_size_estimator.py` | Power \u002F sample-size for means, proportions, survival | n\u002Fa (design-driven) |\n| `scripts\u002Fendpoint_selector.py` | 5-dimension endpoint scoring + classification + surrogate flag | drug, device, biologic, diagnostic, digital-therapeutic |\n| `scripts\u002Fphase_gate_scorer.py` | Feasibility 0-100 + GO\u002FGO-WITH-CONDITIONS\u002FREDESIGN\u002FNO-GO + owners | drug, device, biologic, diagnostic, digital-therapeutic |\n\nAll three: stdlib-only, `--help`, `--sample`, `--output {human,json}`.\n\n## Onboarding & customization\n\nRun the onboarding questionnaire **once before you start** — it captures your defaults and named owners so every tool in this skill is pre-configured. Customization is the point: the answers actually change tool behavior.\n\n```bash\npython3 scripts\u002Fonboard.py            # interactive (also: --defaults, --set key=value, --reset)\npython3 scripts\u002Fonboard.py --show     # see the questions + current effective config\n```\n\nAnswers are saved to `~\u002F.config\u002Fresearch-ops\u002Fclinical-research.json` (global) or `.\u002F.research-ops\u002Fclinical-research.json` (`--scope project`) and are read automatically by `config_loader.py`. They set the default development-area **profile**, default **alpha \u002F power \u002F dropout**, and the named **biostatistician \u002F medical monitor \u002F regulatory owner** printed on outputs. CLI flags always override saved config; `RESEARCH_OPS_NO_CONFIG=1` ignores it entirely.\n\n**The seven questions:** development area · alpha · power · dropout · biostatistician · medical monitor · regulatory owner.\n\n## Optimize with autoresearch (opt-in)\n\nThis skill ships an **isolated, opt-in** bridge to `engineering\u002Fautoresearch-agent`. Only when you ask to \"optimize\" \u002F \"run a loop\" does an autoresearch experiment iteratively improve a study plan against this skill's own feasibility score. `scripts\u002Far_evaluator.py` is the ground-truth evaluator; it prints `feasibility_composite: \u003C0-100>` (higher is better).\n\n```bash\n\u002Far:setup --domain custom --name trial-feasibility \\\n  --target study.json \\\n  --eval \"python3 ar_evaluator.py --target study.json\" \\\n  --metric feasibility_composite --direction higher\n\u002Far:loop custom\u002Ftrial-feasibility\n```\n\nIsolated: no hard dependency — autoresearch runs only on demand, and the loop edits `study.json`, never the evaluator (locked ground truth).\n\n## References\n\n- `references\u002Fstudy_design_canon.md` — ICH E8(R1) general considerations; ICH E9 + E9(R1) estimand addendum; CONSORT 2010; SPIRIT 2013; FDA Multiple Endpoints guidance (2022).\n- `references\u002Fendpoint_and_power.md` — Cohen *Statistical Power Analysis*; Schoenfeld (1983) survival sample size; FDA Surrogate Endpoint Table \u002F BEST glossary; FDA PRO guidance (2009); Chow, Shao & Wang *Sample Size Calculations in Clinical Research*.\n- `references\u002Ftrial_operations.md` — ICH E6(R2\u002FR3) GCP; TransCelerate risk-based monitoring; FDA RBM guidance; CTTI recruitment best practices; site-feasibility scoring literature.\n\n## Assumptions\n\n- Sample-size formulas use normal approximations with a built-in z-table. They are first-pass **estimates**; a biostatistician produces the final justification (and may use simulation, adaptive designs, or exact methods).\n- The endpoint scorer applies *customary* regulatory priors per development area via `--profile`. Company- or indication-specific precedent overrides the prior.\n- The phase-gate scorer bakes in a profile cost-per-patient benchmark; pass a real budget to override the default.\n- An unvalidated surrogate cannot anchor a PRIMARY endpoint — the scorer enforces this with a penalty.\n\n## Anti-patterns\n\n- **Presenting a power estimate as fact.** Every output is an estimate with a named owner who must sign.\n- **Powering for a convenience effect size.** The effect must trace to a published or anchor-based MCID, not to the n you can afford.\n- **Anchoring a primary on an unvalidated surrogate.** Surrogate endpoints need validation evidence for the indication.\n- **Ignoring multiplicity.** More than one primary endpoint requires pre-specified alpha allocation.\n- **Skipping dropout inflation.** Raw n undersizes the study; inflate by 1\u002F(1 − dropout).\n\n## Distinct from\n\n| Sibling \u002F neighbor | Scope | Difference |\n|---|---|---|\n| `ra-qm-team` | ISO 13485 QMS, ISO 14971 risk, EU MDR tech docs + clinical evaluation, FDA 510(k)\u002FPMA\u002FDe Novo\u002FQSR submission | That is the **submission**; clinical-research designs the **study** beforehand |\n| `research\u002Fgrants` | NIH funding discovery + positioning | That **finds funding**; this **designs the trial** |\n| `product-team\u002Fexperiment-designer` | Live product A\u002FB hypothesis + sample size | That is a **product experiment**; this is a **clinical trial** |\n| `research-finance` (sibling) | R&D program budget + burn | That **funds** the program; this **scopes** the study |\n\n## Quick examples\n\n```bash\npython3 scripts\u002Fsample_size_estimator.py --sample\npython3 scripts\u002Fsample_size_estimator.py --design proportions --p1 0.30 --p2 0.45 --dropout 0.15\npython3 scripts\u002Fendpoint_selector.py --sample\npython3 scripts\u002Fphase_gate_scorer.py --sample --output json\n```\n\nThe sample correctly flags an unvalidated serum-cytokine surrogate (cannot be primary) and ranks PASI-75 as the PRIMARY endpoint; the phase-gate sample returns a verdict with a named owner chain.\n\n## Forcing-question library (Matt Pocock grill discipline)\n\nWalked one at a time by `\u002Fcs:grill-research-ops` or the orchestrator. Recommended answer + canon citation per question. Never bundled.\n\n1. **\"Is your primary endpoint a clinical outcome or a surrogate — and if surrogate, is it on FDA's validated table?\"**\n   Recommended: clinical outcome unless the surrogate is validated for this indication.\n   Canon: FDA Surrogate Endpoint Table; BEST (Biomarkers, EndpointS, and other Tools) glossary.\n\n2. **\"What's the minimal clinically important difference you're powering for — and where did that number come from?\"**\n   Recommended: a published or anchor-based MCID, cited; never a convenience effect size.\n   Canon: ICH E9; Cohen *Statistical Power Analysis*.\n\n3. **\"What dropout rate are you assuming, and is the sample size inflated for it?\"**\n   Recommended: inflate n by 1\u002F(1 − dropout) using a justified rate.\n   Canon: Chow, Shao & Wang; ICH E9(R1).\n\n4. **\"Single primary endpoint or multiple — and if multiple, what's the multiplicity control?\"**\n   Recommended: pre-specify alpha allocation (hierarchical \u002F Bonferroni).\n   Canon: FDA Multiple Endpoints guidance (2022).\n\n5. **\"Who is the named biostatistician \u002F medical monitor \u002F regulatory owner signing this synopsis?\"**\n   Recommended: name them now — this output is a recommendation, not a protocol.\n   Canon: ICH E6(R2) GCP roles & responsibilities.\n\nWalk depth-first. Lock 1-2 before opening 3-5. After all are answered, invoke `endpoint_selector.py` → `sample_size_estimator.py` → `phase_gate_scorer.py`.\n","# clinical-research\n\nProspective clinical study DESIGN: endpoints, sample size \u002F power, and phase-gate feasibility. Every output is an **estimate with stated assumptions** routed to a **named human owner**. This skill never gives clinical advice as fact and never substitutes for a biostatistician or regulatory affairs.\n\n## Purpose\n\nR&D clinical teams, medical monitors, and biostatistics functions live at the moment between *we-have-a-hypothesis* and *we-have-a-protocol-ready-for-submission*. This skill structures three of the hardest design decisions:\n\nThree deterministic tools:\n\n1. `sample_size_estimator.py` — Closed-form power \u002F sample-size for two-arm **means** (Cohen's d), **proportions** (normal approximation), and **survival** (Schoenfeld events). Inflates for dropout. Prints an \"ESTIMATE — confirm with a biostatistician\" banner.\n2. `endpoint_selector.py` — Scores candidate endpoints across 5 weighted dimensions (clinical relevance, measurability, regulatory acceptance, sensitivity-to-change, burden) and classifies each as **PRIMARY \u002F KEY-SECONDARY \u002F EXPLORATORY**. Penalizes unvalidated surrogate endpoints.\n3. `phase_gate_scorer.py` — Scores a study plan 0-100 across recruitment feasibility, endpoint readiness, statistical power, operational complexity, and budget fit; returns **GO \u002F GO-WITH-CONDITIONS \u002F REDESIGN \u002F NO-GO** plus the named owners who must sign.\n\n## When to use\n\nInvoke this skill when:\n\n- You are choosing a primary endpoint and need to defend it against surrogate-endpoint scrutiny.\n- You need a defensible first sample-size estimate for a protocol synopsis.\n- A study plan needs a feasibility read before a phase-gate review.\n- You are pressure-testing whether the planned enrollment is achievable given the eligible population and sites.\n\n**Do NOT use this skill to**: prepare a regulatory submission or clinical evaluation report (use `ra-qm-team`), find or position a grant (use `research\u002Fgrants`), design a live product A\u002FB experiment (use `product-team\u002Fexperiment-designer`), or replace a biostatistician's final sample-size justification.\n\n## Workflow\n\n1. **Draft the synopsis** — Fill `assets\u002Fprotocol_synopsis_template.md` (objectives, design, population, endpoints, statistical plan placeholder, owners-to-sign).\n2. **Select the endpoint** — Run `endpoint_selector.py --input endpoints.json --profile {drug|device|biologic|diagnostic|digital-therapeutic}`. Read the classification + surrogate flags. If >1 primary, plan multiplicity control.\n3. **Estimate the sample size** — Run `sample_size_estimator.py --design {means|proportions|survival} ...`. Trace the effect\u002Fdifference\u002FHR to a published or anchor-based source; inflate for dropout.\n4. **Score feasibility** — Run `phase_gate_scorer.py --input study.json --profile \u003Csame> --phase {1|2|3|4}`. Read the verdict + blockers + named owners.\n5. **Route for sign-off** — Assemble the synopsis + estimates into the gate packet. The packet is **a recommendation**; a biostatistician, medical monitor, and regulatory owner sign.\n\n## Scripts\n\n| Script | Purpose | Profiles |\n|---|---|---|\n| `scripts\u002Fsample_size_estimator.py` | Power \u002F sample-size for means, proportions, survival | n\u002Fa (design-driven) |\n| `scripts\u002Fendpoint_selector.py` | 5-dimension endpoint scoring + classification + surrogate flag | drug, device, biologic, diagnostic, digital-therapeutic |\n| `scripts\u002Fphase_gate_scorer.py` | Feasibility 0-100 + GO\u002FGO-WITH-CONDITIONS\u002FREDESIGN\u002FNO-GO + owners | drug, device, biologic, diagnostic, digital-therapeutic |\n\nAll three: stdlib-only, `--help`, `--sample`, `--output {human,json}`.\n\n## Onboarding & customization\n\nRun the onboarding questionnaire **once before you start** — it captures your defaults and named owners so every tool in this skill is pre-configured. Customization is the point: the answers actually change tool behavior.\n\n```bash\npython3 scripts\u002Fonboard.py            # interactive (also: --defaults, --set key=value, --reset)\npython3 scripts\u002Fonboard.py --show     # see the questions + current effective config\n```\n\nAnswers are saved to `~\u002F.config\u002Fresearch-ops\u002Fclinical-research.json` (global) or `.\u002F.research-ops\u002Fclinical-research.json` (`--scope project`) and are read automatically by `config_loader.py`. They set the default development-area **profile**, default **alpha \u002F power \u002F dropout**, and the named **biostatistician \u002F medical monitor \u002F regulatory owner** printed on outputs. CLI flags always override saved config; `RESEARCH_OPS_NO_CONFIG=1` ignores it entirely.\n\n**The seven questions:** development area · alpha · power · dropout · biostatistician · medical monitor · regulatory owner.\n\n## Optimize with autoresearch (opt-in)\n\nThis skill ships an **isolated, opt-in** bridge to `engineering\u002Fautoresearch-agent`. Only when you ask to \"optimize\" \u002F \"run a loop\" does an autoresearch experiment iteratively improve a study plan against this skill's own feasibility score. `scripts\u002Far_evaluator.py` is the ground-truth evaluator; it prints `feasibility_composite: \u003C0-100>` (higher is better).\n\n```bash\n\u002Far:setup --domain custom --name trial-feasibility \\\n  --target study.json \\\n  --eval \"python3 ar_evaluator.py --target study.json\" \\\n  --metric feasibility_composite --direction higher\n\u002Far:loop custom\u002Ftrial-feasibility\n```\n\nIsolated: no hard dependency — autoresearch runs only on demand, and the loop edits `study.json`, never the evaluator (locked ground truth).\n\n## References\n\n- `references\u002Fstudy_design_canon.md` — ICH E8(R1) general considerations; ICH E9 + E9(R1) estimand addendum; CONSORT 2010; SPIRIT 2013; FDA Multiple Endpoints guidance (2022).\n- `references\u002Fendpoint_and_power.md` — Cohen *Statistical Power Analysis*; Schoenfeld (1983) survival sample size; FDA Surrogate Endpoint Table \u002F BEST glossary; FDA PRO guidance (2009); Chow, Shao & Wang *Sample Size Calculations in Clinical Research*.\n- `references\u002Ftrial_operations.md` — ICH E6(R2\u002FR3) GCP; TransCelerate risk-based monitoring; FDA RBM guidance; CTTI recruitment best practices; site-feasibility scoring literature.\n\n## Assumptions\n\n- Sample-size formulas use normal approximations with a built-in z-table. They are first-pass **estimates**; a biostatistician produces the final justification (and may use simulation, adaptive designs, or exact methods).\n- The endpoint scorer applies *customary* regulatory priors per development area via `--profile`. Company- or indication-specific precedent overrides the prior.\n- The phase-gate scorer bakes in a profile cost-per-patient benchmark; pass a real budget to override the default.\n- An unvalidated surrogate cannot anchor a PRIMARY endpoint — the scorer enforces this with a penalty.\n\n## Anti-patterns\n\n- **Presenting a power estimate as fact.** Every output is an estimate with a named owner who must sign.\n- **Powering for a convenience effect size.** The effect must trace to a published or anchor-based MCID, not to the n you can afford.\n- **Anchoring a primary on an unvalidated surrogate.** Surrogate endpoints need validation evidence for the indication.\n- **Ignoring multiplicity.** More than one primary endpoint requires pre-specified alpha allocation.\n- **Skipping dropout inflation.** Raw n undersizes the study; inflate by 1\u002F(1 − dropout).\n\n## Distinct from\n\n| Sibling \u002F neighbor | Scope | Difference |\n|---|---|---|\n| `ra-qm-team` | ISO 13485 QMS, ISO 14971 risk, EU MDR tech docs + clinical evaluation, FDA 510(k)\u002FPMA\u002FDe Novo\u002FQSR submission | That is the **submission**; clinical-research designs the **study** beforehand |\n| `research\u002Fgrants` | NIH funding discovery + positioning | That **finds funding**; this **designs the trial** |\n| `product-team\u002Fexperiment-designer` | Live product A\u002FB hypothesis + sample size | That is a **product experiment**; this is a **clinical trial** |\n| `research-finance` (sibling) | R&D program budget + burn | That **funds** the program; this **scopes** the study |\n\n## Quick examples\n\n```bash\npython3 scripts\u002Fsample_size_estimator.py --sample\npython3 scripts\u002Fsample_size_estimator.py --design proportions --p1 0.30 --p2 0.45 --dropout 0.15\npython3 scripts\u002Fendpoint_selector.py --sample\npython3 scripts\u002Fphase_gate_scorer.py --sample --output json\n```\n\nThe sample correctly flags an unvalidated serum-cytokine surrogate (cannot be primary) and ranks PASI-75 as the PRIMARY endpoint; the phase-gate sample returns a verdict with a named owner chain.\n\n## Forcing-question library (Matt Pocock grill discipline)\n\nWalked one at a time by `\u002Fcs:grill-research-ops` or the orchestrator. Recommended answer + canon citation per question. Never bundled.\n\n1. **\"Is your primary endpoint a clinical outcome or a surrogate — and if surrogate, is it on FDA's validated table?\"**\n   Recommended: clinical outcome unless the surrogate is validated for this indication.\n   Canon: FDA Surrogate Endpoint Table; BEST (Biomarkers, EndpointS, and other Tools) glossary.\n\n2. **\"What's the minimal clinically important difference you're powering for — and where did that number come from?\"**\n   Recommended: a published or anchor-based MCID, cited; never a convenience effect size.\n   Canon: ICH E9; Cohen *Statistical Power Analysis*.\n\n3. **\"What dropout rate are you assuming, and is the sample size inflated for it?\"**\n   Recommended: inflate n by 1\u002F(1 − dropout) using a justified rate.\n   Canon: Chow, Shao & Wang; ICH E9(R1).\n\n4. **\"Single primary endpoint or multiple — and if multiple, what's the multiplicity control?\"**\n   Recommended: pre-specify alpha allocation (hierarchical \u002F Bonferroni).\n   Canon: FDA Multiple Endpoints guidance (2022).\n\n5. **\"Who is the named biostatistician \u002F medical monitor \u002F regulatory owner signing this synopsis?\"**\n   Recommended: name them now — this output is a recommendation, not a protocol.\n   Canon: ICH E6(R2) GCP roles & responsibilities.\n\nWalk depth-first. Lock 1-2 before opening 3-5. After all are answered, invoke `endpoint_selector.py` → `sample_size_estimator.py` → `phase_gate_scorer.py`.\n",{"name":5,"tags":24,"author":32,"license":15,"version":33,"description":7,"compatible_tools":34},[25,5,26,27,28,29,30,31],"research-ops","study-design","endpoint","sample-size","power","phase-gate","biostatistics","claude-code-skills","2.9.0",[35,36,37,38,39,40],"claude-code","codex-cli","cursor","antigravity","opencode","gemini-cli","main","229636be8dd3adf33e35a2aa95b85dc022251d6b",".agents\u002Fskills\u002Falirezarezvani\u002Fresearch-ops__clinical-research","https:\u002F\u002Fgithub.com\u002FPrudhviraj101\u002FX_Agent","https:\u002F\u002Fgithub.com\u002FPrudhviraj101","B.Tech CSE (AI\u002FML) Student | Building practical software with AI 🚀 | AI\u002FML Developer | Building AI agents, intelligent automation & real-world software ","2026-10-02 21:19:59",{"source":8,"skillName":5,"commands":49,"prompt":59,"zipAvailable":60},[50,53,56],{"tool":51,"command":52},"npx","npx skills add Prudhviraj101\u002FX_Agent --skill clinical-research",{"tool":54,"command":55},"bunx","bunx skills add Prudhviraj101\u002FX_Agent --skill clinical-research",{"tool":57,"command":58},"pnpm","pnpm dlx skills add Prudhviraj101\u002FX_Agent --skill clinical-research","安装技能，技能地址：https:\u002F\u002Fgithub.com\u002FPrudhviraj101\u002FX_Agent\u002Fblob\u002Fmain\u002F.agents\u002Fskills\u002Falirezarezvani\u002Fresearch-ops__clinical-research\u002FSKILL.md",true,[62,68,74,78,82,88,92,96,100,104],{"path":63,"resourceType":64,"resourceTypeDesc":65,"sizeBytes":66,"sourceHtmlUrl":67},"assets\u002Fprotocol_synopsis_template.md","ASSET","资产文件",1950,"https:\u002F\u002Fgithub.com\u002FPrudhviraj101\u002FX_Agent\u002Fblob\u002Fmain\u002F.agents\u002Fskills\u002Falirezarezvani\u002Fresearch-ops__clinical-research\u002Fassets\u002Fprotocol_synopsis_template.md",{"path":69,"resourceType":70,"resourceTypeDesc":71,"sizeBytes":72,"sourceHtmlUrl":73},"references\u002Fendpoint_and_power.md","REFERENCE","参考文档",3110,"https:\u002F\u002Fgithub.com\u002FPrudhviraj101\u002FX_Agent\u002Fblob\u002Fmain\u002F.agents\u002Fskills\u002Falirezarezvani\u002Fresearch-ops__clinical-research\u002Freferences\u002Fendpoint_and_power.md",{"path":75,"resourceType":70,"resourceTypeDesc":71,"sizeBytes":76,"sourceHtmlUrl":77},"references\u002Fstudy_design_canon.md",3078,"https:\u002F\u002Fgithub.com\u002FPrudhviraj101\u002FX_Agent\u002Fblob\u002Fmain\u002F.agents\u002Fskills\u002Falirezarezvani\u002Fresearch-ops__clinical-research\u002Freferences\u002Fstudy_design_canon.md",{"path":79,"resourceType":70,"resourceTypeDesc":71,"sizeBytes":80,"sourceHtmlUrl":81},"references\u002Ftrial_operations.md",2957,"https:\u002F\u002Fgithub.com\u002FPrudhviraj101\u002FX_Agent\u002Fblob\u002Fmain\u002F.agents\u002Fskills\u002Falirezarezvani\u002Fresearch-ops__clinical-research\u002Freferences\u002Ftrial_operations.md",{"path":83,"resourceType":84,"resourceTypeDesc":85,"sizeBytes":86,"sourceHtmlUrl":87},"scripts\u002Far_evaluator.py","SCRIPT","脚本",2754,"https:\u002F\u002Fgithub.com\u002FPrudhviraj101\u002FX_Agent\u002Fblob\u002Fmain\u002F.agents\u002Fskills\u002Falirezarezvani\u002Fresearch-ops__clinical-research\u002Fscripts\u002Far_evaluator.py",{"path":89,"resourceType":84,"resourceTypeDesc":85,"sizeBytes":90,"sourceHtmlUrl":91},"scripts\u002Fconfig_loader.py",4101,"https:\u002F\u002Fgithub.com\u002FPrudhviraj101\u002FX_Agent\u002Fblob\u002Fmain\u002F.agents\u002Fskills\u002Falirezarezvani\u002Fresearch-ops__clinical-research\u002Fscripts\u002Fconfig_loader.py",{"path":93,"resourceType":84,"resourceTypeDesc":85,"sizeBytes":94,"sourceHtmlUrl":95},"scripts\u002Fendpoint_selector.py",6783,"https:\u002F\u002Fgithub.com\u002FPrudhviraj101\u002FX_Agent\u002Fblob\u002Fmain\u002F.agents\u002Fskills\u002Falirezarezvani\u002Fresearch-ops__clinical-research\u002Fscripts\u002Fendpoint_selector.py",{"path":97,"resourceType":84,"resourceTypeDesc":85,"sizeBytes":98,"sourceHtmlUrl":99},"scripts\u002Fonboard.py",5551,"https:\u002F\u002Fgithub.com\u002FPrudhviraj101\u002FX_Agent\u002Fblob\u002Fmain\u002F.agents\u002Fskills\u002Falirezarezvani\u002Fresearch-ops__clinical-research\u002Fscripts\u002Fonboard.py",{"path":101,"resourceType":84,"resourceTypeDesc":85,"sizeBytes":102,"sourceHtmlUrl":103},"scripts\u002Fphase_gate_scorer.py",9390,"https:\u002F\u002Fgithub.com\u002FPrudhviraj101\u002FX_Agent\u002Fblob\u002Fmain\u002F.agents\u002Fskills\u002Falirezarezvani\u002Fresearch-ops__clinical-research\u002Fscripts\u002Fphase_gate_scorer.py",{"path":105,"resourceType":84,"resourceTypeDesc":85,"sizeBytes":106,"sourceHtmlUrl":107},"scripts\u002Fsample_size_estimator.py",8739,"https:\u002F\u002Fgithub.com\u002FPrudhviraj101\u002FX_Agent\u002Fblob\u002Fmain\u002F.agents\u002Fskills\u002Falirezarezvani\u002Fresearch-ops__clinical-research\u002Fscripts\u002Fsample_size_estimator.py",[109,118,126,134,141,149],{"skillNo":110,"name":111,"nameZh":6,"description":112,"descriptionZh":6,"repositoryFullName":8,"ownerLogin":9,"ownerAvatarUrl":10,"ownerAccountNo":11,"ownerDisplayName":12,"repositoryNo":13,"starsCount":14,"licenseSpdxId":113,"licenseFileUrl":114,"sourceHtmlUrl":115,"categories":116,"keywords":117,"publishedAt":19},"01M7DQMKNKM6F5G21PPJNW3HR5","webapp-testing","Toolkit for interacting with and testing local web applications using Playwright. Supports verifying frontend functionality, debugging UI behavior, capturing browser screenshots, and viewing browser logs.","Apache-2.0","https:\u002F\u002Fgithub.com\u002FPrudhviraj101\u002FX_Agent\u002Fblob\u002Fmain\u002F.agents\u002Fskills\u002Fwebapp-testing\u002FLICENSE.txt","https:\u002F\u002Fgithub.com\u002FPrudhviraj101\u002FX_Agent\u002Fblob\u002Fmain\u002F.agents\u002Fskills\u002Fwebapp-testing\u002FSKILL.md",[],[],{"skillNo":119,"name":120,"nameZh":6,"description":121,"descriptionZh":6,"repositoryFullName":8,"ownerLogin":9,"ownerAvatarUrl":10,"ownerAccountNo":11,"ownerDisplayName":12,"repositoryNo":13,"starsCount":14,"licenseSpdxId":113,"licenseFileUrl":122,"sourceHtmlUrl":123,"categories":124,"keywords":125,"publishedAt":19},"01M7DQMF21V9VHCTVS8H5JFNJM","web-artifacts-builder","Suite of tools for creating elaborate, multi-component claude.ai HTML artifacts using modern frontend web technologies (React, Tailwind CSS, shadcn\u002Fui). Use for complex artifacts requiring state management, routing, or shadcn\u002Fui components - not for simple single-file HTML\u002FJSX artifacts.","https:\u002F\u002Fgithub.com\u002FPrudhviraj101\u002FX_Agent\u002Fblob\u002Fmain\u002F.agents\u002Fskills\u002Fweb-artifacts-builder\u002FLICENSE.txt","https:\u002F\u002Fgithub.com\u002FPrudhviraj101\u002FX_Agent\u002Fblob\u002Fmain\u002F.agents\u002Fskills\u002Fweb-artifacts-builder\u002FSKILL.md",[],[],{"skillNo":127,"name":128,"nameZh":6,"description":129,"descriptionZh":6,"repositoryFullName":8,"ownerLogin":9,"ownerAvatarUrl":10,"ownerAccountNo":11,"ownerDisplayName":12,"repositoryNo":13,"starsCount":14,"licenseSpdxId":113,"licenseFileUrl":130,"sourceHtmlUrl":131,"categories":132,"keywords":133,"publishedAt":19},"01M7DQM8HREQ0DN1HV12K0W3VT","theme-factory","Toolkit for styling artifacts with a theme. These artifacts can be slides, docs, reportings, HTML landing pages, etc. There are 10 pre-set themes with colors\u002Ffonts that you can apply to any artifact that has been creating, or can generate a new theme on-the-fly.","https:\u002F\u002Fgithub.com\u002FPrudhviraj101\u002FX_Agent\u002Fblob\u002Fmain\u002F.agents\u002Fskills\u002Ftheme-factory\u002FLICENSE.txt","https:\u002F\u002Fgithub.com\u002FPrudhviraj101\u002FX_Agent\u002Fblob\u002Fmain\u002F.agents\u002Fskills\u002Ftheme-factory\u002FSKILL.md",[],[],{"skillNo":135,"name":136,"nameZh":6,"description":137,"descriptionZh":6,"repositoryFullName":8,"ownerLogin":9,"ownerAvatarUrl":10,"ownerAccountNo":11,"ownerDisplayName":12,"repositoryNo":13,"starsCount":14,"licenseSpdxId":15,"licenseFileUrl":6,"sourceHtmlUrl":138,"categories":139,"keywords":140,"publishedAt":19},"01M7DQM5J7B71CQ8EVHBXCCCN2","systematic-planning","Formulate crisp, executable multi-phase implementation plans for non-trivial features, refactors, and architectural migrations. Use before writing code on any task with multiple files, uncertain requirements, or breaking changes.","https:\u002F\u002Fgithub.com\u002FPrudhviraj101\u002FX_Agent\u002Fblob\u002Fmain\u002F.agents\u002Fskills\u002Fsystematic-planning\u002FSKILL.md",[],[],{"skillNo":142,"name":143,"nameZh":6,"description":144,"descriptionZh":6,"repositoryFullName":8,"ownerLogin":9,"ownerAvatarUrl":10,"ownerAccountNo":11,"ownerDisplayName":12,"repositoryNo":13,"starsCount":14,"licenseSpdxId":113,"licenseFileUrl":145,"sourceHtmlUrl":146,"categories":147,"keywords":148,"publishedAt":19},"01M7DQKG6WREWGRRCKHCJS96Y1","slack-gif-creator","Knowledge and utilities for creating animated GIFs optimized for Slack. Provides constraints, validation tools, and animation concepts. Use when users request animated GIFs for Slack like \"make me a GIF of X doing Y for Slack.\"","https:\u002F\u002Fgithub.com\u002FPrudhviraj101\u002FX_Agent\u002Fblob\u002Fmain\u002F.agents\u002Fskills\u002Fslack-gif-creator\u002FLICENSE.txt","https:\u002F\u002Fgithub.com\u002FPrudhviraj101\u002FX_Agent\u002Fblob\u002Fmain\u002F.agents\u002Fskills\u002Fslack-gif-creator\u002FSKILL.md",[],[],{"skillNo":150,"name":151,"nameZh":6,"description":152,"descriptionZh":6,"repositoryFullName":8,"ownerLogin":9,"ownerAvatarUrl":10,"ownerAccountNo":11,"ownerDisplayName":12,"repositoryNo":13,"starsCount":14,"licenseSpdxId":113,"licenseFileUrl":153,"sourceHtmlUrl":154,"categories":155,"keywords":156,"publishedAt":19},"01M7DQJY7AN1XCX6G3ACA5K4JH","skill-creator","Create new skills, modify and improve existing skills, and measure skill performance. Use when users want to create a skill from scratch, edit, or optimize an existing skill, run evals to test a skill, benchmark skill performance with variance analysis, or optimize a skill's description for better triggering accuracy.","https:\u002F\u002Fgithub.com\u002FPrudhviraj101\u002FX_Agent\u002Fblob\u002Fmain\u002F.agents\u002Fskills\u002Fskill-creator\u002FLICENSE.txt","https:\u002F\u002Fgithub.com\u002FPrudhviraj101\u002FX_Agent\u002Fblob\u002Fmain\u002F.agents\u002Fskills\u002Fskill-creator\u002FSKILL.md",[],[]]